by EpicentRx | May 29, 2020 | 2020, Press Releases
TORREY PINES, Calif., May 29, 2020 — EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company’s chief executive officer. Dr. Reid who is a...
by EpicentRx | Mar 3, 2020 | 2020, Press Releases
EpicentRx’s lead program is the first-in-class small molecule CD47 antagonist RRx-001 in Phase 3 for small cell lung cancer Enrollment of Phase I trial for adenovirus program AIM-001 expected to begin this year Close of recent $35M series D will advance AIM-001 and...
by EpicentRx | Mar 18, 2019 | Conferences
March 2019, Atlanta, Georgia Abstract: Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells
by EpicentRx | Nov 18, 2018 | Conferences
November 2018, Washington, D.C. Abstract: BETATRAP, a replication competent type 5 adenovirus carrying a TGF-beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
by EpicentRx | Nov 18, 2018 | Conferences
November 2018, New Orleans, Louisiana Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
